Supplementary Table 1.

Findings of studies reviewed from other meta-analyses

Authors	Year	Patient population	Type of Intervention	Outcomes
Kramer et al.29	2000	20 patients with cirrhosis who developed HE (ACLF); median age: 56 years, range: 33–71 years, 13 men	BioLogic-DT (n = 10)	Decreased platelet count (from 75 to 26 g/L; p = 0.01) and fibrinogen (from 185 to 106 mg/dL; p < 0.001) level Increased INR (from 2.0 to 2.2; p < 0.001) Decreased creatinine (from 1.0 to 0.9; p = 0.007) and BUN (from 28 to 25; p = 0.01) No change in albumin, bilirubin, AST, ALT or ammonia
Kramer et al.30	2002	8 cirrhotic patients with hepatorenal syndrome; etiologies: -alcoholic (6) -Hepatitis C (1) -Cryptogenic (1)	Prometheus (n = 8)	Significant decreases in bilirubin (p = 0.002), BUN (p = 0.02) and creatinine (p < 0.001) from baseline No incidences of bleeding or hemodynamic instability observed
Stadlbauer et al.31	2006	8 patients with ACLF: -alcoholic cirrhosis (4) -Chronic HCV (1) -Metastatic colon cancer (1) -Liver graft dysfunction (1)	MARS and Prometheus, cross-over (n = 8)	No significant changes in serum levels of any cytokine were found after treatments with MARS or Prometheus In MARS treatments, IL-10 was cleared from plasma more efficiently than IL-6 Clearance of IL-10 was higher in Prometheus than in MARS treatments.
Stadlbauer et al.32	2007	8 patients with ACLF: -alcoholic cirrhosis (4) -Chronic HCV (1) -Metastatic colon cancer (1) -Liver graft dysfunction (1)	MARS and Prometheus, cross-over (n = 8)	Total and individual bile acids were removed efficiently by both systems With both devices, absolute reduction of chenodeoxycholic acid (CDCA) was higher than that of cholic acid (CA) Reduction ratios were significantly higher for CA than for CDCA in Prometheus, no difference with MARS
Klammt et al.33	2008	24 patients with ACLF	MARS (n = 12)	Improvement of albumin binding capacity was more frequent in the albumin dialysis group than in the control group
Dethloff et al.34	2008	24 patients under evaluation for liver transplant: -Alcoholic cirrhosis (15) -Hepatitis C (2) -Autoimmune (2) -PBC, porthyria, cholesterol storage disorder, hemochromartosis, unknown (1 each)	Prometheus (n = 8) MARS (n = 8) Hemodialysis (control, n = 8)	Increase in arterial pressure in the MARS group (P = 0.008) Significant decrease in creatinine levels in the MARS (P = 0.03) and hemodialysis (P = 0.04)groups Decreased platelet count in the Prometheus group (P = 0.04)
Iarustovski et al.35	2014	26 patients with ALF and MODS as postoperative complications after cardiac surgery	MARS (n = 9) Prometheus (n = 17)	Decreased in serum total bilirubin (8.6% in MARS-group (p = 0.028) and 33% in Prometheus-group (p < 0.001)) Decreased unconjugated bilirubin levels (29% in Prometheus-group (p = 0.003))
Klammt et al.36	2014	24 patients with a decompensation of a pre-existing cirrhosis (ACLF) with severe hyperbilirubinemia (total serum bilirubin >20 mg/dL)	MARS (n = 12)	11 out of 12 patients (91.7%) in the MARS group survived the study period; 6/12 patients (50%) in the control group died No relationship was found between the decline of platelet count and the number of consecutive treatments
Sponholz et al.37	2016	32 patients with ALF, ACLF and graft failure	MARS and SPAD	Plasma bilirubin levels were significantly reduced by both systems (MARS: median −68 μmol/L, p = 0.001; SPAD: −59 μmol/L, p = 0.001) Only MARS significantly reduced bile salts (−39 μmol/L, p < 0.001), creatinine (−24 μmol/L, p < 0.001) and urea (−0.9 mmol/L, p = 0.024) Albumin-binding capacity was increased by MARS (+10%, p < 0.001)